医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Dr. Reddy’s to Release Q2 FY15 Results on October 29, 2014

2014年10月17日 PM06:38
このエントリーをはてなブックマークに追加


 

HYDERABAD, India

Dr. Reddy’s Laboratories (NYSE: RDY) will announce results for the Second Quarter ended September 30, 2014 on Wednesday, October 29, 2014 after the Board Meeting. The results will be available on the Company’s website www.drreddys.com.

Summary of Events

Event     Date and Time     Medium
Release of financial results October 29th, after the Board Meeting

Email, Media, Company website, Business Wire

Earnings Call October 29th, 6.30 PM IST / 9:00 AM EDT

Hosted by the Company (Details below)

Webcast of Earnings Call October 29th, 6.30 PM IST / 9.00 AM EDT through Nov 3rd, 2014

URL available on Company’s website, www.drreddys.com

Transcript of the Earnings call Will be available on the Company’s website

URL available on Company’s website, www.drreddys.com

 

Earnings Call

Following the release, the management of the Company will host an earnings call to discuss the Company’s financial performance.

Conference Dial-In Numbers
Primary Number:     +91 22 3960 0616
Secondary Number:     +91 22 6746 5826
The numbers listed above are universally accessible from all networks and all countries.
6000 1221

Available in – Ahmedabad, Bangalore, Bhubaneswar, Chandigarh, Chennai, Coimbatore, Delhi, Goa, Guntur, Gurgaon, Hyderabad, Indore, Jamshedpur, Kanpur, Kochi/Cochin, Kolhapur, Kolkata, Nagpur, Noida, Patna, Pune, Raipur, Rajkot, Surat, Trivandrum, Vadodara, Vijayawada

Local Access Number:

Accessible from all major carriers except BSNL/MTNL.

3940 3977

Available in Ahmedabad, Bangalore, Chandigarh, Chennai, Kochi/Cochin, Gurgaon (NCR), Hyderabad, Kolkata, Lucknow, Pune

     

Accessible from all carriers.

USA: 1 866 746 2133

International Toll Free Number:

UK: 0 808 101 1573

Singapore: 800 101 2045

     

Hong Kong: 800 964 448

 

No password/pin number is necessary to dial in to any of the other calls. As participation in the call is limited, early registration is encouraged. The operator will provide instructions on asking questions before and during the call.

Audio Webcast

The audio webcast of the earnings call will be available to all interested parties at www.drreddys.com. Please visit the web site at least fifteen minutes ahead of the scheduled start time to register and to download and install any necessary audio software. Participants in the webcast can listen to the proceedings, but will not be able to ask questions. The replay will be available 2 hours after the earnings call, through November 3rd, 2014. For play back dial in phone No: 022 3065 1212 and ID: 375#.

Transcript

The transcript of the earnings call will also be available on the Company’s website.

About Dr. Reddy’s

Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Major therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infective. Major markets include India, USA, Russia-CIS and Europe apart from other select geographies within Emerging Markets.

For more information, log on to: www.drreddys.com

*EDT- Eastern Daylight Saving Time

CONTACT

Dr. Reddy’s Laboratories Ltd.
Investor Relations:
Kedar
Upadhye, +91 40 66834297
kedaru@drreddys.com
or
Saunak
Savla, +91 40 49002135
saunaks@drreddys.com
or
Ashish
Girotra (USA), +1 609-375-9805
ashishg@drreddys.com

同じカテゴリーの記事 

  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表
  • The Office of Health Economics: Adult Vaccination Programmes Deliver Socio-economic Benefits up to 19 Times Initial Investment, According to New Report
  • Masimo创始人兼首席执行官Joe Kiani将在智利举行的全球患者安全峰会上谈论人工智能
  • マシモ創業者兼最高経営責任者(CEO)のジョー・キアニがチリで開催される世界患者安全サミットでAIについて講演
  • Codone Biotech to Present Data on its Suppressor-tRNA Platform in Disease Models with Nonsense Mutations (Premature Termination Codons)